Enzon Pharmaceuticals, Inc. (ENZN)
$10.17
-0.20 (-1.93%)
| CAPS Rating |
|
|---|---|
| Open | $10.15 |
| Previous Close | $10.37 |
| Daily Range | $10.12 - $10.37 |
| 52-Week Range | $4.37 - $10.80 |
| Market Cap | $462.28M |
| P/E Ratio | 518.50 |
| Dividend (Yield) | N/A (N/A) |
| Volume | 178,309 |
| Average Daily Volume | 667,000 |
ENZN
VS S&P 500 (SPY)
How do you think ENZN will perform vs the S&P 500?
Caps
Motley Fool CAPS is a community working together to find better stocks and to become better investors.
ENZN Advanced Details
- CAPS Community Analysis: Commentary, Scorecard
- Advanced Financial Analysis: Historical Prices, Chart, Stats, Ratios, Earnings/Growth Rates, Statements, SEC Filings
ENZN News and Commentary
- UPDATE 1-Enzon to sell specialty pharma unit – Reuters
- When Breaking Up Isn't Hard to Do – The Motley Fool
- Icahn's Spotty Track Record – The Motley Fool
- Seattle Genetics Has What Others Want – The Motley Fool
- PDL Shakeup Lifts Shares – The Motley Fool
- Enzon Shareholders Steal the Show – The Motley Fool
- CVT's Copacetic Cash Management – The Motley Fool
- Activist Investor Attack at Endo – The Motley Fool
- Breaking Down a Biotech's Assets – The Motley Fool
Related News and Articles
- This Big Winner Has Hit Its Prime – The Motley Fool
- Dream Stocks for Biotech Investors – The Motley Fool
- Still Enjoying Those Acquisitions, Pfizer? – The Motley Fool
- Novartis Didn't Know JAK, Until Now – The Motley Fool
- 4 Platform Drugmakers to Invest In – The Motley Fool
- 10 Stocks Shaking the Market – The Motley Fool
- A Big Upgrade for Allos Therapeutics – The Motley Fool
- Now's a Great Time to Invest -- So Don't Blow It Like This – The Motley Fool
- This Stock Is a Train Wreck – The Motley Fool
RSS Headlines
Fool UK
